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Recent advances in extracellular signaling suggest that extracellular protein phosphorylation is a regulatory
mechanism outside the cell. The list of reported active extracellular protein kinases and phosphatases is growing,
and phosphorylation of an increasing number of extracellular matrix molecules and extracellular domains of
trans-membrane proteins is being documented. Here, we use public proteomic databases, collagens – the major
components of the extracellular matrix, extracellular signaling molecules and proteolytic enzymes as examples to
assess what the roles of extracellular protein phosphorylation may be in health and disease. We propose that novel tools
be developed to help assess the role of extracellular protein phosphorylation and translate the findings for biomedical
applications. Furthermore, we suggest that the phosphorylation state of extracellular matrix components as well as the
presence of extracellular kinases be taken into account when designing translational medical applications.
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Technical advances have significantly contributed to in-
sights into the functional role of extracellular protein
phosphorylation. Most recently, protein kinases such as
VLK and FAM20C (also known as Golgi casein kinase),
have been shown to be secreted through the classical
ER-Golgi secretory pathway [1,2]. In addition, several
protein kinases and phosphatases, including PKA [3,4],
PKC [5,6], CKII [7], alkaline phosphatase [8], tartrate-
resistant acid phosphatase (TRAP) [9] and the PTEN
phosphatase [10], have been shown to accumulate in
conditioned cell culture media of different cell lines [11],
as well as in human plasma and/or serum samples from
cancer patients [12]. Furthermore, these kinases have
been shown to be functional in conditioned serum-free
cell culture media [13] and/or sera [14]. At the same
time, a large number of extracellular matrix and cell
surface proteins and extracellular domains of trans-
membrane proteins, including fibronectin [15], vitronec-
tin [16], osteopontin [17], collagens [13], fibrinogen [18],* Correspondence: bjorn_olsen@hms.harvard.edu
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unless otherwise stated.laminin [19], CD36 [20], β-amyloid precursor protein
(APP) [21], T-cell-receptor complex (TCR) [22] and
many others, have been reported to be phosphorylated
[23] in vitro and in vivo. At what stages in their
secretory pathway such proteins may serve as substrates
for kinases is not clear. In principle, phosphorylation of
secretory proteins could happen prior to secretion or in
the extracellular matrix (ECM). In either case, changes
in phosphorylation may have important functional con-
sequences. Alterations in phosphorylation of secreted
proteins during their transit through the secretory path-
way might interfere with their folding, transport, secre-
tion, release from the cell surface or interaction with
other ECM components. Phosphorylation and dephos-
phorylation events in the ECM may regulate the pro-
cessing, assembly, degradation and binding properties of
matrix proteins. In any case, the widespread phosphoryl-
ation of extracellular matrix proteins suggests that the
mechanism of reversible protein phosphorylation may
not only be a mechanism inside cells as widely demon-
strated, but may also be a regulatory mechanism outside
cells. How important such kinase activity maybe for the
functions of extracellular proteins is well illustrated bytral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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severe disorders. For example, the Raine syndrome is
caused by loss-of-function mutations in the FAM20C
protein kinase [1]. Mutations leading to lethal and non-
lethal forms of this disease were shown to prevent secre-
tion and reduce the activity in the extracellular matrix
[1]. It is believed that impairment of the phosphorylation
state of small integrin-binding ligands, N-linked glycopro-
teins (SIBLINGs), accounts for the observed biomineraliza-
tion defects in Raine syndrome. The sites phosphorylated
by FAM20C (at the sequence motif S-x-E) bind calcium
and regulate the formation of calcium phosphate-
containing hydroxyapatite (HA) crystals [24]. One pro-
tein in the SIBLING group, osteopontin (OPN), inhibits
HA formation, and this inhibition depends on the de-
gree of phosphorylation [25]. In addition, the recently
described secreted kinase VLK has been found to have
an important role during morphogenesis [2]. Knocking
Vlk out in mice leads to severe defects in morphogen-
esis in multiple tissues and death within a day after
birth. The exact mechanism has not been identified,
but the findings support the notion that secreted
kinases are important in health and disease [26-29].
Understanding the mechanisms and functional roles of
extracellular protein phosphorylation may open up
opportunities for novel disease treatments [30]. A well-
known example of the importance of the phosphoryl-
ation state of a drug for its efficiency is the Multiple
Sclerosis drug Fingolimod (FTY720). The phosphoryl-
ation state of FTY720 is believed to be regulated by the
ecto-phosphatase LPP3 in vivo [31].
Secretion pathways and extracellular ATP
Since VLK and FAM20C kinases are translated with a
signal peptide it is easy to understand that they can be
secreted from cells into the extracellular matrix. Other
members of this protein family and closely related to
FAM20C, such as FAM20A, FAM20B [32], FAM198,
Four-jointed box protein 1 (FJX1) [33], also contain a signal
peptide and are very likely secreted [1]. In addition to these
reported examples, a large number of other kinases are pre-
dicted to have a signal peptide that may be secreted [34].
Examples include the FAM69 family members or the VLK
kinase (previously PKDCC) with high sequence similarity
to the FAM69 family [35]. In contrast, the protein kinases
PKA [36], PKC [37], CKI [38], CKII [38,39], and the
alkaline phosphatases [40] which have all been found on
the external surface of the cell membrane [11], do not have
a signal peptide. This raises the question of how they
get to their extracellular destinations. Considering the
fact that well-known secreted proteins without a signal
peptide, such as interleukin 1 [41], galectin 1 and 3
[42], HMGB1 [43], FGFs [44] and others [44], use
unconventional secretory pathways, it is likely thatkinases may use similar mechanisms. Exosomes and
microvesicles are among such unconventional secre-
tion mechanisms [44]. Protein kinases A, C and the
casein kinase II have been reported to be secreted in
prostasomes, secretory granules of epithelial cells of
the prostate [45]. Alkaline phosphatase [46], PTEN
phosphatase [47] and the tissue-nonspecific phosphatase
[48] were all shown to be secreted in exosomes. These ki-
nases and phosphatases are then associated with the outer
surface of the cell membrane [37,40,49]. Their release from
the cell surface into the extracellular matrix (ECM) can be
induced under cell culture conditions [37,39,50].
A sufficiently high ATP concentration is essential for
extracellular phosphorylation to occur. ATP concentra-
tions in human plasma were reported in a range of
30nM-11μM in different studies and under different
conditions [51]. Furthermore, extracellular ATP concen-
trations of 1-5μM were reported in vivo in tissues of
healthy mice compared to the enhanced concentration
of at least 700μM at tumor sites [52]. Several physio-
logical and pathophysiological events are known to in-
crease the extracellular ATP concentration, including
wounds [53], inflammation [54], ischemia [55], hypoxia
[56], platelet aggregation [57], sympathetic nerve stimu-
lation [58] or cellular damage [51] (for review see [23]).
In addition, a number of regulated mechanisms were
shown to lead to secretion of ATP in vesicles from nerve
cells, mast cells, platelets, and T cells [11,59]. Alterna-
tively, ATP synthase was shown to generate ATP at the
cell surface from cAMP and ADP [60]. Thus a large
number of mechanisms have been described to lead to
ATP secretion into the ECM and fulfill the precondition
of ATP availability for extracellular phosphorylation to
occur.
Nearly all collagen types, the major components of the
ECM, can occur in phosphorylated states as shown by
mass spectrometry data
Large scale data mining has revealed that a large number
of extracellular and cell surface proteins, and extracellu-
lar domains of trans-membrane proteins can exist in
phosphorylated states [23]. Among these proteins are
the 28 members of the collagen protein family, the most
abundant protein family in mammals and constituting
up to 30% of the total protein content in the human
body [61]. Mass spectrometry data for collagens show
that collagen phosphorylation is much more common
than previously thought; nearly all collagens can occur
in phosphorylated states in different species (Figure 1,
Additional file 1: Table S1). Even if only a fraction of
these data can be validated, most collagens would be
represented. Further support comes from curated and
highly reliable databases that contain a large number of
double checked phosphorylated sites in extracellular
Figure 1 Experimentally verified phosphorylated sites for collagens. The experimentally verified phosphorylated sites were retrieved from the
databases Phosida, PhosphoSitePlus, PhosphoNet, HPRD, dbPTM and UniProt. Collagen structures are represented as described [61]. The color
code used to represent the position of the phosphorylated sites is red (human), blue (mouse) and black (rat).
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dues within the collagen molecules suggests that the phos-
phorylation could affect a variety of specific functions. For
example, a large number of phosphorylated sites are located
in triple helical regions of all fibril-forming collagens. Phos-
phorylation at these sites may affect the polymerization of
the molecules into fibrillar structures or interactions be-
tween fibrils and other extracellular matrix components.
Phosphorylation of sites in the propeptide domains of
procollagens could affect proteolytic cleavage of the pro-
peptides. The extracellular domains of all membrane-
associated collagens contain at least one phosphorylated
site, which might be important in ECM-cell signaling or
proteolytic cleavage of the surface domains. Furthermore,
all network-forming and short-chain collagens [63] contain
phosphorylated residues. Moreover, with the exception of
collagen α1 (IX) and α1 (XXI), all fibril-associated collagenswith interrupted triple helices (FACIT collagens) [64] are
heavily phosphorylated. Both members of the multiplexin
family of collagens (XV and XVIII) contain phosphorylated
residues. Finally, except collagen chains α4 (VI), α1 (X) and
α1 (XXVI), all remaining collagen chains appear to be
phosphorylated. The phosphorylation map for collagens
presented here is far from being complete and represents
the current status of available data. A more directed study
of collagen phosphorylation is likely to lead to discovery of
additional phosphorylated sites in these extracellular matrix
molecules.
Phosphorylation at residues close to the N- and C-
propeptide cleavage sites may affect processing of
fibrillar procollagen to collagen
Protein phosphorylation in the ECM may well be a mech-
anism to regulate protein processing and degradation.
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mote or prevent proteolytic enzyme binding. Indeed, many
in vitro studies support this possibility. Whether such
events happen in vivo needs to be demonstrated. Phosphor-
ylation of vitronectin at position S362 reduces its cleavage
by plasmin at the position R361-S362 [65]. Phosphorylation
of complement component C3 by the surface kinase of the
human parasite Leishmania, leads to more resistance to
cleavage by trypsin compared with the nonphosphorylated
form [66]. Phosphorylation of S8 of β-amyloid by ecto-PKA
strongly inhibits its degradation by angiotensin-converting
enzyme (ACE) [67]. Protein phosphorylation is also part of
a mechanism that regulates shedding of transmembrane
collagens from the cell surface. For example, phosphoryl-
ation of collagen XVII, a member of the family of trans-
membrane collagens, has been shown to regulate the
proteolytic shedding of the triple-helical domain from the
cell surface. Collagen XVII mediates adhesion of the epider-
mis to the dermis by interacting with the β4 integrin via its
cytoplasmic region. The collagen XVII ectodomain is con-
stitutively shed from the cell surface by metalloproteinases
of the ADAM (a disintegrin and metalloproteinase) family.
This process is inhibited by phosphorylation of collagen
XVII at an extracellular site, S544, located 5 residues
downstream of the TACE (ADAM17) cleavage site
[13] (Figure 2A). Furthermore, sera of patients with
bullous pemphigoid, a chronic autoimmune skin dis-
ease, contain autoantibodies preferentially recognizing
phosphorylated collagen XVII [68].
Similarly, phosphorylation of other collagens, most
notably fibril forming collagens, could be of physio-
logical importance in the processing of procollagen
to collagen by affecting cleavage of the N- and C-
propeptides. Many phosphorylated sites are located close
to the cleavage sites in procollagen α1 (I), α2 (I), α1 (II)
and α1 (III) (Figure 2B-E). BMP1, in tandem with the
procollagen C-proteinase enhancer-1 (PCPE-1), binds to
the procollagens and catalyzes the proteolytic cleavage
of the C-propeptide. PCPE-1 regulates substrate binding
and activity of BMP1 through binding to the procollagen
C-propeptide trimer. Interestingly, amino acid residues
that are 35 residues downstream of the BMP1 cleavage
site have been reported to be critical for PCPE-1 binding
and consequently for BMP1 binding and activity [69].
Striking is the fact that collagens I-III contain multiple
phosphorylated sites in the PCPE-1 binding region,
which might affect the binding and therefore cleavage at
the C-propeptide sites (Figure 2B-E).
The N-propeptide cleavage is mediated by ADAMTS2
[70]. Three phosphorylated sites have been shown to be
located 10, 11 and 15 residues downstream of the cleav-
age site of ADAMTS2 in procollagen α1(I). Meprin α
and β have been recently reported to cleave the collagen
N- and C-propeptides [71]. It is intriguing that thephosphorylated sites described above are only 4, 5, and 9
residues downstream of the N-propeptide meprin cleav-
age site. Phosphorylation at these sites is likely to affect
the three-dimensional structure of the binding region
for both ADAMTS2 and the meprins and might affect
the rate of processing. In addition to the already verified
phosphorylation sites, bioinformatic servers predict a
large number of potential phosphorylation sites in the
propeptides of collagens I, II and III, and some are lo-
cated even closer to the cleavage regions. The same is
true for the C-propeptide cleavage regions. One phos-
phorylated site is located 16 residues downstream of the
BMP1 cleavage site and 7 residues downstream of the
meprin α and β cleavage site in collagen α1 (I); clearly
within the PCPE-1 binding region [69]. In the C-
propeptide of procollagen α2(I), one experimentally veri-
fied phosphorylated site is located 5 residues upstream
of the meprin α and β cleavage site and 15 residues up-
stream of the BMP1 cleavage site at the C-terminus.
Other phosphorylated sites are located 19, 22 and 28
residues downstream of the BMP1 cleavage site, and one
of these residues is known to lead to severe Osteogenesis
Imperfecta type III, when mutated to P (boxed) [72].
Both propeptides of procollagen α1(II) contain verified
phosphorylation sites; however, they are located at sites
that are unlikely to affect the binding of ADAMTS2 or
PCPE-1 and BMP1. Procollagen α1(III) contains one
phosphorylated site 16 residues downstream of the
BMP1 and meprin α and β C-propeptide cleavage site
and many more further away.
Phosphorylation of single collagen chains in the
endoplasmic reticulum may have an effect on triple helix
formation and fibril and fiber properties at a later stage
Reversible protein phosphorylation plays a major role in
protein synthesis, folding and secretion [73]. Several
phosphorylated sites have been identified in the procol-
lagen α1(I), α2(I), α1(II) and α1(III) chains in both the
triple-helical regions and propeptide domains (Figure 1).
Recently, the C-propeptide domain of procollagen
α1(III) was crystallized and the structural mechanism
during intracellular trimerization deciphered [74]
(Figure 3A). The association of chains is governed by
the chain recognition sequence (CRS), a discontinuous
sequence of 15 amino acids found in procollagen
α1(I), α2(I), α1(II) and α1(III). While there are no re-
ported phosphorylated sites directly located in the
chain recognition sequences, it is interesting to note
that the procollagen α1(I), α2(I), α1(II) chains contain
S-x-E motifs in the sequence, recognized by the
FAM20C kinase which is known to be active in the
Golgi apparatus [1] (Figure 3B). Another interesting
fact is that the already reported phosphorylated sites
are partially highly conserved; whether these have
Figure 2 (See legend on next page.)
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Figure 2 Procollagen processing by ADAMTS2, BMP1 and TACE. A.: Cleavage of the ecto-domain of collagen α1(XVII) by TACE. The sequence of
the cleavage site of TACE (box) and the phosphorylated residues (highlighted in red) are shown. The color coding to represent the position of
the phosphorylated sites used is red (human) and blue (mouse). Collagen structures are represented as described [61]. B-E.: Cleavage of the
N- and C-propeptide of collagen I-III. The sequences of the N- and C-propeptide are shown in the box. Experimentally verified phosphorylated
sites (red letters) and known mutations (black bold) leading to diseases are highlighted. Cleavage site of the enzymes are marked. Collagen
structures are represented as described [61].
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T1148 in the C-propeptide region of the human pro-
collagen α2(I) chain has been shown by mass spec-
trometry to be phosphorylated [72] (Figure 3B, boxed).
This residue is mutated to proline in a case of severe
Osteogenesis Imperfecta type III; the mutation delays
triple helix formation and causes reduced secretion of the
mutant molecules [72]. While replacement of threonine by
proline may affect protein folding in this region, this raises
the question of whether loss of a phosphorylation site may
contribute to the disease phenotype. Support for a some-
what similar possibility comes from the effect of a mutation
in enamelin, whereby an S216L substitution leads to loss
of phosphorylation. Enamelin is phosphorylated by the
FAM20C kinase at this position and the phosphorylated
residue mediates calcium binding. The loss of phosphoryl-
ation at this position is regarded as the main reason for the
disease Amelogenesis Imperfecta [75]. Phosphoryl groups
that are attached to collagens α1(I) and α2 (I) chains inside
the cell and are carried on the procollagen molecules as
they are secreted into the ECM may have an effect on as-
sembly into collagen fibrils. Given the triple-helical collagen
structure, the phosphoryl groups would be located on the
surface of the triple helix.
Phosphorylation may regulate extracellular protein
interactions
Phosphorylation of proteins is a common mechanism to
regulate their binding to other proteins inside the cell.
This mechanism may be exploited outside the cell too,
as cell culture and in vitro studies show. For example,Figure 3 Multiple sequence alignment of the trimerization domain. A.: Top
chain recognition sequence (CRS) is highlighted in orange and green and the e
alignment of the C-propeptide domain of procollagen I-III. The chain re
and the experimentally verified phosphorylated sites are shown in red.
Osteogenesis Imperfecta [72]. Motifs recognized by FAM20C are highligphosphorylation by PKC of T92 in the ectodomain of a
membrane receptor for collagen and thrombospondin,
CD36, leads to increased binding of collagen, but loss of
thrombospondin binding; dephosphorylation reverses
the effect [76,20]. Phosphorylation of S378 in vitronectin
by PKA, adjacent to the binding sites for heparin, PAI-1
and plasminogen, reduces its binding to plasminogen
and PAI-1 [77]. Phosphorylation of vitronectin at resi-
dues T50 and T57, close to the RGD integrin binding
site at residues 45–47, enhances cell adhesion and accel-
erates cell spreading [16]. Phosphorylation of the extra-
cellular domain of the Nogo-A receptor by CKII at the
position S281 inhibits ligand binding [78].
Collagen binding to PEDF, heparin and heparin sulfate
proteoglycans
One key interacting partner of collagens is heparin.
Heparin recognizes a region in collagens V and XI con-
taining a series of conserved arginine residues [79].
Interestingly, the collagen α2(XI) chain contains a phos-
phorylated site in this region only 3 residues upstream
and downstream of two of the conserved arginines [79]
(Additional file 1: Table S1). In addition, another phos-
phorylated site is located in the same binding region in
collagen α2(V) [79]. Phosphorylation at these residues
may well affect heparin binding.
Pigment epithelium-derived factor (PEDF) is another
important collagen binding partner. It has recently been
discovered that the sequence IKGHRGFSGL in the C-
terminal region of the human collagen α1(I) chain is a
high affinity binding motif for PEDF. The motif overlapsview of C-propeptide domain of procollagen α1(III) [74]. The discontinuous
xperimentally verified phosphorylated sites in red. B.: Multiple sequence
cognition sequence is highlighted in an orange and green box
The boxed residue corresponds to a known mutation leading to
hted in bold black.
Figure 4 S-x-E sequence motifs in collagens. Locations of S-x-E (or S-x-Sp, whereby the second serine needs to be phosphorylated) motifs recognized by
the FAM20C kinase in the collagens are highlighted [1]. The color code used for the sequence pattern S-x-E is red (human), blue (mouse) and black (rat).
Reported motifs known to be phosphorylated are marked with a star. Collagen structures are represented as described [61].
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KGHRG(F/Y) [80]. It is interesting to note that one
phosphorylated serine residue is located only 9 residues
downstream of the PEDF binding sequence (Additional
file 1: Table S1). PEDF itself is known to be phosphory-
lated extracellularly in human plasma by the kinase CKII
at residues S24 and S114 and by PKA at residue S227.
Phosphorylation of S24 and S114 by CKII abolishes
PEDF neurotrophic activity but enhances its antiangio-
genic activity; phosphorylation of S227 reduces the anti-
angiogenic activity [81].
Collagen-integrin binding
Collagens contain many cell binding sites that are recog-
nized by integrins, including RGD sites. Phosphorylation
close to RGD sites may interfere with cell binding. This
has already been described for collagen α3(IV). CollagenIV is a major component of basement membranes. A
domain within collagen IV molecules, the Goodpasture
antigen, plays an important role in the Goodpasture syn-
drome, a disease whereby autoimmune antibodies attack
the lung and kidney. The antigen was shown to be phos-
phorylated in vitro at a serine residue next to an RGD
sequence (RGDS). In addition, the Goodpasture antigen
was isolated in phosphorylated and non-phosphorylated
forms from human kidney, suggesting that the phos-
phorylation may have a role in the disease [82]. Likewise,
other collagens are reported to be phosphorylated close
to the RGD site including human collagen α2(IV) at
residue S1446 (SAVPGFRGD), human collagen α3(IV) at
the residue S1435 (RGDS), mouse collagen α2(V) at the
residue S137 (SQGPRGD), human collagen α3(VI) at
residue S2048 (RGDRGPIGSIG), human collagen α2(XI)
at residue T576 (RGDT) and human collagen α1(XXII)
Figure 5 Phosphorylated residues in MMPs and BMPs. A.: Phosphorylated residues in MMPs. B.: Phosphorylated residues in BMPs. The
experimentally verified phosphorylated sites were retrieved from the databases Phosida, PhosphoSitePlus, PhosphoNet, HPRD, dbPTM and
UniProt. The structures are represented as used in the PhosphoSitePlus database. The color code used to represent the position of the
phosphorylated sites is red (human), blue (mouse) and black (rat).
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Phosphorylation at all these sites may well affect integrin
binding.
The role of collagen phosphorylation in bone
mineralization
Important components of the mineralized matrix of bone
and dentin are secreted phosphoproteins belonging to the
SIBLING family (osteopontin, bone sialoprotein, dentin sia-
lophosphoprotein, matrix extracellular phosphoglycopro-
tein, dentin matrix protein 1 and many others) [83,24,84].
Phosphorylation of these proteins is important for bone
mineralization; however, the stage at which they are phos-
phorylated is not well understood [83,85,86]. Early studies
suggested that extracellular protein kinase CKII plays a
key role in the mechanism [87,88]. In vitro phosphoryl-
ation of S136 in bone sialoprotein has been shown to
enhance its ability to nucleate hydroxyapatite [84]. Fur-
thermore, dephosphorylation by tartrate-resistant acid
phosphatase (TRAP) is regulating osteoclast migration
on phosphorylated osteopontin [89]. It has been sug-
gested that this mechanism could control the depth
and area of each osteoclastic bone resorption site by
triggering osteoclast detachment and facilitating migra-
tion on the bone surface [89]. Furthermore, ectosomeshave been reported to contain high concentrations of
TRAP and to be released during calcification [90]. It is
believed that TRAP is promoting hydroxyapatite forma-
tion and bone mineralization. While phosphorylated
collagen was already reported in 1966 [91], the role
of collagen phosphorylation in mineralization is less
understood. As discussed above, several of the reported
phosphorylated sites in the collagens are located within
the sequence motif S-x-E recognized by the serine/
threonine kinase FAM20C (Figure 4). The locations of
many of the motifs are highly conserved among differ-
ent species. Only a fraction of these motifs in collagens
has been shown to be phosphorylated by mass spec-
trometry analyses, but even the limited data available
suggest that phosphorylation in general and FAM20C
phosphorylation in particular might be important for
collagen functions related to biomineralization.
Phosphorylation of matrix-associated proteolytic enzymes
and growth factors such as MMPs and BMPs
MMPs
The matrix metalloproteinase MMP2 was reported to be
regulated by PKC phosphorylation [92]. Human recom-
binant MMP2 expressed in mammalian cells was shown
by mass spectrometry to be phosphorylated at residues
Yalak and Olsen Journal of Translational Medicine  (2015) 13:125 Page 9 of 11T250, Y271 and S365. All three phosphorylated sites are lo-
cated in the collagen-binding domain and the phosphoryl-
ation affects the activity of MMP2; dephosphorylation leads
to increased activity, while phosphorylation diminishes the
activity [92,93]. Nearly all MMPs have been reported to be
partially or heavily phosphorylated, but the effects of the
phosphorylation state on function remain to be studied
(Figure 5A, Additional file 2: Table S2).
BMPs
Recombinant human BMP15, as well as growth and dif-
ferentiation factor (GDF)-9, has been reported to be
phosphorylated [94]. Further studies have demonstrated
that BMP15 is phosphorylated by the FAM20C kinase at
residue S6 and that this phosphorylation is required for
biological activity [95]. In addition to these specific ex-
amples almost all bone morphogenetic proteins (BMPs),
have been reported to be phosphorylated (Figure 5B,
Additional file 3: Table S3). Their phosphorylation state
may influence their activity. For example, BMP1 cleavage
by furin at position R120 (RSRSRR-AA) leads to its
activation. While there are no phosphorylated residues
close to this cleavage site in the sequence, a potential
site that might be recognized by FAM20C is located dir-
ectly in the recognition sequence [96].
Conclusion
Our insights into extracellular protein phosphorylation
have grown during the last 40 years. With novel tech-
niques and methods, the field has experienced a recent
revival leading to astonishing and promising findings
[10]. As shown in the example of collagens, several func-
tions of extracellular matrix components may be regu-
lated by extracellular protein phosphorylation. With the
facts indicating that nearly all collagen types, MMPs and
BMPs can occur in both phosphorylated and nonpho-
sphorylated forms, we believe that phosphorylation may
well represent a mechanism for regulating their func-
tions. We speculate that extracellular protein kinases in
tandem with extracellular protein phosphatases might
have fundamental roles in the regulation of biochemical
processes in the extracellular matrix. A better under-
standing of the role of extracellular protein phosphoryl-
ation of collagens and other extracellular proteins may
have significant impact on cancer research, tissue engin-
eering, regenerative medicine, biomarker development
and drug design. Extracellular protein phosphorylation
may affect the function of extracellular matrix, cell sur-
face and transmembrane proteins and consequently cell
behavior at large. Last but not least, there are currently a
large number of experimentally verified phosphorylated
sites for the proteins analyzed here. The fact that only a
few sites have been shown to have functional conse-
quences, suggests that many more examples will bediscovered in the future. Furthermore, only a few of the
reported sites here can be assigned to known extracellu-
lar protein kinases indicating that other protein kinases
must account for the overwhelming majority of the
phosphorylated sites. We thus speculate that novel
extracellular protein kinases and phosphatases remain to
be discovered. Their identification will open up new per-
spectives on the regulation of extracellular matrix func-
tions and how to manipulate these functions in health
and disease by stimulating the design of novel chemical
compounds that target the extracellular matrix. Novel
techniques have helped generate deep insights into the
function of intracellular protein phosphorylation and led
to a large number of small kinase inhibitors [97-100].
Applying such tools for studies and regulation of extra-
cellular phosphorylation events may help decipher the
functional roles of extracellular protein kinases and lead
to novel and potent inhibitors for drug design.
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